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Pharmacotherapy and Pregnancy
Highlights from the fi rst international conference for individualized   
pharmacotherapy in pregnancy 
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Gideon Koren, MD6, Anne Zajicek, MD7, PharmD, Wayne R. Snodgrass, MD2, PhD, David A. Flockhart, MD PhD1 
H alf of the world’s population is women. The majority of women become pregnant, and 
many of those women take some kind of 
medication during their pregnancy, even 
if only for a short time. Th e majority of 
drugs have not been rigorously studied in 
pregnant women to determine the most 
effective dose with the least potential 
for adverse eff ects. Instead, women are 
given “cookie-cutter” therapy, using doses 
extrapolated from nonpregnant women, 
men, or pregnant animals. Th is can lead 
to problems.
Instead, individualization of 
pharmacotherapy in pregnancy promises 
to take individual women and determine 
the optimal dose and drug for them to 
maximize the effect of the drug while 
attempting to minimize the side eff ects to 
them and their unborn babies. Because 
this fi eld of study is underrepresented, 
we held a conference to bring together researchers and experts 
to discuss current knowledge, issues, and challenges surrounding 
individualized pharmacotherapy in pregnancy. Speakers came from 
the NIH, the Food and Drug Administration (FDA), and various 
research centers in the United States and Canada. Below are the 
summaries of the discussions at the conference. Full notes from the 
panel discussions are available from the authors on request.
Individualized Medicine in Pregnancy
Pregnancy is a time when drugs are commonly used. In pregnancy, 
there is a particularly keen need for high effi  cacy due to the high 
risk of toxicity for 2 or more patients. Th ere is much less data for 
drugs in pregnancy than there is even in pediatrics. A Medline 
search of the terms “individualized therapy” and “pregnancy” 
revealed no articles that dealt with both. 
Genetic variation is a potentially valuable biomarker for many 
drug eff ects.1 Th ere are clinical examples of steroids used in asthma, 
digoxin, and warfarin where some heterogeneity in response has 
been linked to genotype variation. One of the more important 
enzymes in pharmacogenetics is cytochrome P450 (CYP) 2D6, 
which metabolizes drugs such as codeine, antidepressants, and some 
beta blockers. Th is enzyme is absent in about 7% of Caucasians and 
is hyperactive in 30% of East Africans. Changes 
in CYP2D6 have been demonstrated to have a 
profound impact in the concentrations of drugs 
like nortriptyline.2 Th e activity of CYPs like 
2D6 also changes during pregnancy. Genotype 
variation in receptors and transporters can also 
alter a drug’s eff ect.1 
Genomics off ers a valuable opportunity to 
develop individualized therapy in pregnancy. 
More data are needed to fully harness the 
potential of pharmacogenetics in pregnancy. 
Additionally, more dynamic biomarkers of 
drug eff ects in pregnancy and the linking of 
specimens to clinical data will help advance 
pharmacogenetics and individualized therapy 
in pregnancy.
The Role of Human Placenta 
in Pharmacotherapy 
The onset of pregnancy is associated with 
changes in maternal physiology to accom-
modate the inception of the fetoplacental unit. 
Th ese physiological changes are a result of “new” metabolic path-
ways as well as the induction or inhibition of enzymes existing in 
maternal liver and extrahepatic tissues. 
Knowledge of placental biodisposition of an administered 
medication during pregnancy is crucial for the following reasons. 
First, the concentration of a drug in the fetal, not maternal, 
circulation aff ects neonatal outcome. Th is distinction is evident 
from the lack of correlation between maternal dose of methadone 
and intensity of neonatal abstinence syndrome. Second, the 
metabolites of an administered drug that are formed by placental 
enzymes may be diff erent from those formed by maternal liver. For 
example, the major metabolite of glyburide formed by placental 
microsomes is diff erent from that formed by maternal liver.3 Th ird, 
biotransformation of a drug to a metabolite could be catalyzed by 2 
diff erent enzymes in the liver and placenta—for example, methadone 
metabolism by hepatic CYP 3A4 and placental aromatase to the 
same metabolite. Fourth, placental uptake and effl  ux transporters 
contribute to the transfer of drugs to the developing fetus or its 
protection, respectively. Th erefore, placental disposition of drugs as 
well as the activity of placental metabolic enzymes during gestation 
contributes to the pharmacokinetics and pharmacodynamics of 
therapeutics administered to pregnant women.
Data are sparse on the effects of medication use 
during pregnancy. 
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Hypertensive Disease
Hypertensive diseases in pregnancy are common and carry with 
them signifi cant mortality and morbidity. In the developing world, 
hypertension signifi cantly contributes to maternal mortality; in the 
developed world, the morbidity is shift ed to the neonate through 
indicated preterm delivery.
Antihypertensive therapy must be individualized to the 
desired pharmacokinetic effect. Most drugs act by changing 
vascular resistance (eg, hydralazine, calcium channel blockers), 
or by reducing cardiac output through a reduction in heart rate 
(eg, beta blockers) or a reduction in stoke volume (eg, diuretics). 
Th erapy should be individualized to the anticipated hemodynamic 
changes during pregnancy itself and with the pathological changes 
associated with chronic hypertension and preeclampsia. Th erapy 
must also be individualized to the fetal condition so that mothers 
are adequately treated but suffi  cient perfusion is maintained so as 
to support fetal growth. 
During pregnancy, CYP3A, CYP2D6, and p-glycoprotein are 
signifi cantly up-regulated, increasing the apparent oral clearance 
of many antihypertensive drugs.4 The resulting changes in 
pharmacokinetics require changes in dosing and frequency of dosing 
of many drugs. Calcium channel blockers, CYP3A substrates, and 
metoprolol, a CYP2D6 substrate, require substantial adjustments. 
Drugs such as atenolol, which undergoes renal clearance, require 
more modest and more predictable adjustments. Clonidine, 
which undergoes renal clearance, also has a signifi cant unknown 
metabolic pathway, making its pharmacodynamics somewhat 
unpredictable. Th e pharmacodynamics of beta blockers, diuretics, 
and calcium channel blockers are more straightforward.
The FDA and Drug Use in Pregnancy
Some published data suggest that women use an average of 4 to 
5 prescription drugs during pregnancy to treat chronic medical 
conditions that require ongoing therapy, acute conditions needing 
timely treatment, and pregnancy-related conditions. Despite the 
number of American women who may become pregnant each 
year, there is not enough information about the safe and eff ective 
use of medicines at this critical time.
Since 1997, the FDA has been working on new regulations that 
will improve the way that prescription medicines are labeled for use 
during pregnancy and lactation. Th e 1979 letter category system 
(A, B, C, D, X) did not consider or address situations when drug 
exposure inadvertently occurred early in pregnancy. Th e FDA also 
found that the pregnancy category system was oft en misinterpreted 
and overly simplifi ed the complex and individualized risk–benefi t 
decision-making process. Th e Proposed Rule for Pregnancy and 
Lactation Labeling is the fi nal piece of Th e Physicians’ Labeling Rule, 
which was implemented in June 2006.5 Th e proposed rule would 
eliminate the pregnancy letter categories and create a detailed and 
structured framework in which to present available data about drug 
use during pregnancy and lactation. While the proposed framework 
uses some standardized statements to convey risk information 
based on human and/or animal data, it relies primarily on narrative 
descriptions of both known and unknown risks, benefi ts, and 
considerations for clinical management. As proposed, both the 
pregnancy and lactation sections of labeling would include a risk 
summary, a clinical considerations section, and data (human fi rst, 
then animal). Th e pregnancy section would also include a standard 
statement about the background risk of having a child with a birth 
defect and pregnancy registry contact information, when available. 
Th e FDA’s Maternal Health Team is also working hard to facilitate 
the FDA’s use of new authorities to collect pregnancy exposure data 
by requiring pregnancy registries.
Provider and Patient Attitudes Toward Genetic Studies 
In order to increase the participation of pregnant women in 
research, investigators must understand some of the barriers to 
participation. Understanding the attitudes of women and their 
health care providers is crucial to facilitating participation in 
research. Although past surveys document a general support for 
biobank research on biological specimens, general knowledge 
about the use of the specimens is low.6 
Women’s health care workers have not been specifi cally surveyed 
regarding their attitudes toward research in pregnancy and genetics. 
Pregnant women have been supportive of cord blood donation 
for years despite a lack of understanding of what happens to the 
specimens. A recent National Institute of Child Health and Human 
Development survey of women with banked specimens documented 
that the majority would grant unrestricted permission for future 
use of their specimens.7 Ethnic minorities were much less likely to 
allow their specimens to be used in the future. Other surveys have 
also demonstrated a general feeling that studies in pregnancy are 
worthwhile, but fewer women note that they are willing to donate 
specimens. Th e recent availability to obtain DNA from saliva as 
opposed to needlestick may improve the willingness of some women 
to participate.8 Educating the public about the importance of this 
research for the care of pregnant women and their babies is imperative 
for the future of pharmacogenetic research in pregnancy.
Consenting for Drug Studies in Pregnancy
In the wake of many revelations of unethical research, including 
problems arising from drugs and research involving medicines 
in pregnant women, children, and the fetus9, the U.S. Congress 
passed the National Research Act in 1974, establishing the National 
Commission for the Protection of Human Subjects of Biomedical 
and Behavioral Research, the country’s fi rst bioethics commission. 
Several commission reports, including “Research on the Fetus” 
and the “Belmont Report,” provided the ethical foundations for 
what would become the U.S. regulatory mechanism to protect 
human subjects from harm, including the Common Rule (45 
CFR 46, Subpart A), the relevant FDA regulations (21 CFR 
50/56), and additional provisions for the protection of other 
vulnerable subjects. Th e informed consent model ensured that 
populations were protected from exploitation, discrimination, 
and the risks of physical harm and moral wrong. Additionally, 
it ensured that populations that were especially vulnerable, 
including pregnant women, were given additional protections. 
Th ese protections made the ethical presumption, for example, that 
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these groups should not be included in research unless there was 
a compelling reason to do so. In 1993, a major shift  occurred in 
U.S. regulatory policy; rather than excluding women and children 
from research, the NIH, through Public Law PL103-43, made clear 
its commitment to requiring that women be included in trials 
unless there was a reason not to. Th is shift  raises the question of 
whether “vulnerability” is still the right model for drug research 
involving pregnant women. Translational research will require 
researchers and regulators to revisit the applicability of the FDA 
and Common Rule informed consent requirements.10 At the very 
least, the postgenome world will demand that informed consent 
procedures and principles for drug studies in pregnant women 
should be revisited.
Ethics of Medication Studies in Pregnancy
Th is panel discussion focused on defi ning vulnerability. Th e 
panelists discussed how a pregnant woman is categorized as 
vulnerable. They noted that the label of “vulnerable” places 
limitations and sometimes burdensome restrictions on the 
principle of equity. More harm may actually come from using 
inadequate information when making clinical decisions than from 
participation in research. Th e panelists also discussed the need for 
new ways to inform patients through the use of videos for those 
who are functionally illiterate.
Treating the Mother, Protecting the Unborn
Th e anxiety women have toward birth defects is tremendous, 
oft en leading them not to take a needed drug. Women exposed 
to a nonteratogenic drug in one study assigned a 25% risk of 
teratogenic eff ects to the drug.11 Women exposed to diagnostic 
radiation assigned a major teratogenic risk to their exposure. Th e 
risk perception can be so great that many women will terminate 
otherwise wanted pregnancies because of it. 
Several conditions highlight the need to balance fears with 
facts when making medication decisions with women. The 
combination of doxylamine and pyridoxine for nausea and 
vomiting of pregnancy (NVP) was removed from the U.S. market 
due to fears and economic pressure from litigation surrounding 
limb reduction defects. Th is action resulted in almost a 3 times 
increase in the rate of hospitalization for NVP and no change 
in the rate of limb reduction defects.12 Women with depression 
oft en stop treatment or receive subtherapeutic doses due to fears 
of adverse eff ects or neonatal withdrawal syndrome. 
Th e major categories of proven medical teratogens include 
anti-epileptics, angiotensin converting enzyme inhibitors, 
lithium, warfarin, isotretinoin, and thalidomide, to name a 
few. Evidence-based counseling for pregnant women would be 
helped greatly if labeling kept up with the evidence. For instance, 
fl uoxetine’s label states that safety of the drug in pregnancy is not 
established despite the presence of six dysmorphology studies, 
three neurodevelopmental studies, and one meta-analysis, all 
documenting the apparent safety of fl uoxetine in pregnancy. We 
must allow evidence-based counseling to guide clinical decisions 
and discuss anxiety and fears honestly with patients. 
The NIH Roadmap and Obstetric Pharmacology
Th ere is a severe lack of research in obstetrics and almost no drug 
development for this underserved population. Lack of research 
translates into poor clinical care for pregnant women and increased 
maternal, fetal, and neonatal morbidity and mortality. Th e Eunice 
Kennedy Shriver National Institute of Child Health and Human 
Development has funded two networks, the Maternal and Fetal 
Medicine Units Network and the Obstetric Pharmacology Research 
Units Network, to address clinical and translational issues in 
obstetrics. Th e NIH Roadmap Initiative is designed to improve 
health through a multidisciplinary approach.13 Pregnancy is a 
complex process, with alterations in maternal, fetal, and placental 
physiology, which the NIH Roadmap Initiative is well suited to 
research. 
Th e NIH Roadmap is divided into three major themes: New 
Pathways to Discovery, to advance understanding of biological 
systems; Research Teams of the Future, including support of high-
risk and interdisciplinary research and public–private partnerships; 
and Re-engineering the Clinical Research Enterprise. Th e NIH 
has solicited grant applications for these initiatives and grants 
have been funded, some in areas of specifi c interest to obstetric 
pharmacology.
Fetal Supraventricular Tachycardia: 
Defi ning the Problem
Fetal supraventricular tachycardia (SVT), with its risk for 
development of hydrops fetalis, is a potentially fatal disorder. 
Currently, no published prospective randomized controlled 
clinical studies exist to assist in guiding drug therapy for fetal 
SVT. Physicians utilize widely varying drug regimens often 
refl ecting personal experience and opinion. A somewhat common 
maternally-administered step-wise antiarrhythmic drug regimen 
is digoxin followed by fl ecainide. Sotalol is added if there is no 
response to prior drug therapy. However, many regimens are used 
in practice.14 Fetal SVT, if persistent for more than 12 hours, may 
progress rapidly to hydrops fetalis in some cases.
Diagnostic capabilities are not uniform in hospitals. 
Widespread use of the fetal cardiovascular profi le score (CVPS) 
might allow increased comparison of case severity and correlation 
to drug response among different referral medical centers. 
The CVPS ranking includes assessment of cardiac function, 
cardiomegaly, and hydrops. Genomics also plays a role in therapy 
as P-glycoprotein transports digoxin out of both maternal and fetal 
circulation, limiting fetal exposure to the therapy. A multicenter 
trial incorporating genomic assessments is needed to optimize 
drug therapy for fetal SVT.
Individualized Use of Antidepressants in Pregnancy
More than 20% of pregnant women have been found to suff er from 
depressive symptoms.15 Women with depression during pregnancy 
have an increased use of alcohol and other substances and worse 
pregnancy outcomes. Maternal depression is also a marker for poor 
infant development.16 Th e mainstay of treatment of these disorders 
has been the selective serotonin reuptake inhibitors (SSRI), with 
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many studies demonstrating effi  cacy and safety. However, recent 
data have questioned the safety of these medications, leading many 
women to discontinue them. It is known that women who quit 
taking antidepressants during pregnancy increase the risk of adverse 
pregnancy outcomes.17 Despite the clinical and societal impact of 
depression during pregnancy, there are no large pharmacokinetic 
datasets to guide clinicians in making rational dosing decisions 
regarding use of SSRI in pregnant women. Although we have made 
great strides in the treatment of depression and in the identifi cation 
of postpartum depression, this lack of pharmacokinetic knowledge 
is an obstacle to adequately treating depression during one of the 
most crucial times in women’s lives. 
Gaps in Knowledge and What Is Needed Next
Th e panel discussed the paucity of data regarding drugs in preg-
nancy and the lack of incentive for companies to perform the 
studies. Th e Safe Drugs for Children Act, which incentivizes drug 
manufacturers with extra time on patent if they provide studies 
on their drug in children, may be a good model for drug studies 
on pregnant women or women of reproductive age. Th e panelists 
also discussed the lack of practitioner loyalty to manufacturers 
who perform the safety studies. Large organizations, like the 
American College of Obstetricians and Gynecologists, as well as 
grassroots movements need to advance the issue of optimizing 
medication therapy for pregnant women. Th e panel discussed the 
need for more studies regarding the eff ect drugs in breast milk 
has on infants. Th e need for long-term infant follow-up in drug 
studies in pregnancy was highlighted. Th e fi nal issues discussed 
were those of knowledge translation and dissemination. Closing 
the knowledge gap involves educating women. Once the research 
about medicines in pregnancy is completed, translating the fi nd-
ings into understandable lay language and ensuring that women 
and practitioners actually hear the message are very important 
issues that need to be addressed. 
Conclusion
Drugs are used by providers for pregnant women for many con-
ditions. Pregnancy-specifi c research, in general, is lacking. Due 
to the eff orts of governmental and academic institutions, a push 
toward individualization of pharmacotherapy in pregnancy is 
occurring. A critical mass of researchers and project funding will 
improve the health of pregnant women by allowing practitioners 
to provide optimal health care to women needing medications in 
pregnancy.
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